This year IRB Barcelona has supervised 39 research projects done by secondary school students
The awardees will present their work in two public science fairs to be held this year
“Diario Médico” has interviewed Antonio Zorzano, group leader of the Complex Metabolic Diseases and Mitochondria Laboratory at IRB Barcelona and full professor at the UB. Zorzano is the coordinator of the Inflames study, led by CIBER, which seeks to identify the mechanisms involved in the inflammatory processes in the obese, type 2 diabetics, and patients with Crohn’s disease, with the aim to obtain new therapeutic strategies for these diseases.
Read the interview in Diario Médico (in Spanish)
Antonio Zorzano heads the three-year study entitled INFLAMES, which has a budget of 679,800 euros provided by the Institute of Health Carlos III.
It is one of the three interdisciplinary projects of excellence started this year in the framework of the Spanish Biomedical Research Network (Centro de Investigación Biomédica en Red (CIBER)
Researchers headed by Antonio Zorzano at IRB demonstrate that the DOR protein promotes muscle mass loss in mice.
The scientists hypothesize that the design of an inhibitor against DOR would serve to prevent and tackle muscle wasting in patients suffering from sarcopenia and cachexia.
Researchers at IRB Barcelona participate in a study headed by IDIBAPS that sheds light on the molecular causes of obesity.
The control of hunger and body weight is governed by the central nervous system, and the region called the hypothalamus plays a crucial role. In normal conditions, the hormone leptin suppresses appetite and reduces body weight by activating the POMC neurons of the hypothalamus.
In obesity there is leptin resistance and this hormone loses its capacity to exert its effects on appetite and weight. The neurobiological causes of this alteration are among the main enigmas in the field of obesity research.
This study describes a molecular mechanism in POMC neurons that explains how leptin resistance comes about and how appetite control becomes disrupted.
The results of a study on the mitochondrial protein Mitofusin-2 by Antonio Zorzano’s team have been echoed in local, national and international media.
Through this new study on Mitofusin-2 published in Embo Journal, Zorzano and his lab reveal that this protein is also an essential component for the general health of the cell.
Read the article in Gaceta Médica (...
A research team at IRB discovers that Mitofusin 2 confers the cell with the sensitivity to understand its state of health, and determine whether it should be repaired or undergo apoptosis
With this new function, Mitofusin 2 becomes a viable target to intervene in diseases such as neurodegeneration and cancer
Genmedica Therapeutics, a biotech company co-founded by IRB Barcelona researcher and coordinator of the Institute's Molecular Medicine Programme Antonio Zorzano, has attracted an investment of 12 million euros from the British venture capital fund, Asclepios Bioresearch. The Catalan start-up company, located in the...
One of the most prestigious biotech and health websites, Fierce Biotech Research, reports on the discovery made by Antonio Zorzano’s group at IRB Barcelona. Published in PNAS, the study addresses the validation of Mitofusin 2 as a posible therapeutic target for type 2 diabetes.
Read the news Fierce Biotech Research (PDF)
Link to Fierce Biotech Research
Link to the...